Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 4486 entries
Sorted by: Best Match Show Resources per page
A prospective comparison of transcutaneous and serum bilirubin within brief time intervals

community settings

Jones DF.
GSID: 0ISG0Rz98f4J
DF Jones, AR McRea, JD Knowles, FC Lin… - Clinical …, 2017 - journals.sagepub.com

The American Academy of Pediatrics recommends screening newborns≥ 35 weeks' gestation with total serum bilirubin (TSB) or transcutaneous bilirubin (TcB) to detect …

Cite
Jones, D. F., McRea, A. R., Knowles, J. D., Lin, F. C., Burnette, E., Reller, L. A., & Lohr, J. A. (2017). A prospective comparison of transcutaneous and serum bilirubin within brief time intervals. Clinical Pediatrics, 56(11), 1013-1017.
Jones, Denise F., et al. "A prospective comparison of transcutaneous and serum bilirubin within brief time intervals." Clinical Pediatrics 56.11 (2017): 1013-1017.
Copy Download .nbib Format: MLA
… with transcutaneous screening versus total serum bilirubin measurement for newborn jaundice in hospital and community settings: a cost-minimization …

community settings

Baerg K.
GSID: OTJmfMEARJcJ
S McClean, K Baerg, J Smith-Fehr… - … Medical Association Open …, 2018 - cmajopen.ca

… In the current study, the estimated cost per TcB screen in hospital and community (urban and rural) settings was $3.54 and $3.76, respectively, whereas the cost per TSB screen was $15.82 in hospital, and $50.21 and $65.03 in...

Cite
McClean, Stephanie, et al. "Cost savings with transcutaneous screening versus total serum bilirubin measurement for newborn jaundice in hospital and community settings: a cost-minimization analysis." Canadian Medical Association Open Access Journal 6.3 (2018): E285-E291.
McClean S. et al. Cost savings with transcutaneous screening versus total serum bilirubin measurement for newborn jaundice in hospital and community settings: a cost-minimization analysis //Canadian Medical Association Open Access Journal. – 2018. – Т. 6. – №. 3. – С. E285-E291.
Copy Download .nbib Format: MLA
Accuracy of transcutaneous bilirubin measurement in newborns after phototherapy

community settings

Zibolen M.
GSID: NLgrCCYH2TcJ
L Casnocha Lucanova, K Matasova, M Zibolen… - Journal of …, 2016 - nature.com

Objective: We tested the accuracy of transcutaneous bilirubin (TcB) measure in newborns undergoing phototherapy. Study Design: In a prospective study of 150 term Caucasian …

Cite
Casnocha Lucanova, L., Matasova, K., Zibolen, M., & Krcho, P. (2016). Accuracy of transcutaneous bilirubin measurement in newborns after phototherapy. Journal of Perinatology, 36(10), 858-861.
Casnocha Lucanova, L., et al. "Accuracy of transcutaneous bilirubin measurement in newborns after phototherapy." Journal of Perinatology 36.10 (2016): 858-861.
Copy Download .nbib Format: MLA
Ameliorative effect of ocimum sanctum on meloxicam induced toxicity in wistar rats.

Toxicology international

Mahaprabhu R, Bhandarkar AG, Jangir BL, Rahangadale SP, Kurkure NV.
PMID: 21976818
Toxicol Int. 2011 Jul;18(2):130-6. doi: 10.4103/0971-6580.84265.

An ameliorating effect of Ocimum sanctum on the toxic effect of meloxicam, a new non-steroidal anti-inflammatory drug was studied by evaluating haemato-biochemical parameters, oxidative stress, gross and histopathological changes in various organs of Wistar rats. A total of thirty-six...

Cite
Mahaprabhu R, Bhandarkar AG, Jangir BL, et al. Ameliorative effect of ocimum sanctum on meloxicam induced toxicity in wistar rats. Toxicol Int. 2011;18(2):130-6doi: 10.4103/0971-6580.84265.
Mahaprabhu, R., Bhandarkar, A. G., Jangir, B. L., Rahangadale, S. P., & Kurkure, N. V. (2011). Ameliorative effect of ocimum sanctum on meloxicam induced toxicity in wistar rats. Toxicology international, 18(2), 130-6. https://doi.org/10.4103/0971-6580.84265
Mahaprabhu, R, et al. "Ameliorative effect of ocimum sanctum on meloxicam induced toxicity in wistar rats." Toxicology international vol. 18,2 (2011): 130-6. doi: https://doi.org/10.4103/0971-6580.84265
Mahaprabhu R, Bhandarkar AG, Jangir BL, Rahangadale SP, Kurkure NV. Ameliorative effect of ocimum sanctum on meloxicam induced toxicity in wistar rats. Toxicol Int. 2011 Jul;18(2):130-6. doi: 10.4103/0971-6580.84265. PMID: 21976818; PMCID: PMC3183620.
Copy Download .nbib Format: NLM
An unusual case of rapidly progressive hyperbilirubinemia.

Case reports in pediatrics

Thornton KM, Nyp MF, Music Aplenc L, Jones GL, Carpenter SL, Guest EM, Shapiro SM, Manimtim WM.
PMID: 24288641
Case Rep Pediatr. 2013;2013:284029. doi: 10.1155/2013/284029. Epub 2013 Oct 29.

We present an unusual case of hyperbilirubinemia with rapid early progression leading to bilirubin encephalopathy in a term neonate. Despite early recognition and intervention, the total serum bilirubin reached a maximum level of 39 mg/dL at 32 hours of...

Cite
Thornton KM, Nyp MF, Music Aplenc L, et al. An unusual case of rapidly progressive hyperbilirubinemia. Case Rep Pediatr. 2013;2013:284029doi: 10.1155/2013/284029.
Thornton, K. M., Nyp, M. F., Music Aplenc, L., Jones, G. L., Carpenter, S. L., Guest, E. M., Shapiro, S. M., & Manimtim, W. M. (2013). An unusual case of rapidly progressive hyperbilirubinemia. Case reports in pediatrics, 2013284029. https://doi.org/10.1155/2013/284029
Thornton, Kimberly M, et al. "An unusual case of rapidly progressive hyperbilirubinemia." Case reports in pediatrics vol. 2013 (2013): 284029. doi: https://doi.org/10.1155/2013/284029
Thornton KM, Nyp MF, Music Aplenc L, Jones GL, Carpenter SL, Guest EM, Shapiro SM, Manimtim WM. An unusual case of rapidly progressive hyperbilirubinemia. Case Rep Pediatr. 2013;2013:284029. doi: 10.1155/2013/284029. Epub 2013 Oct 29. PMID: 24288641; PMCID: PMC3830790.
Copy Download .nbib Format: NLM
Dubin-Johnson syndrome presenting after acute viral hepatitis.

Gastroenterology and hepatology from bed to bench

Lahmi F, Roshani M, Khosravi K, Azizi M, Mohebbi SR, Zali MR.
PMID: 24834177
Gastroenterol Hepatol Bed Bench. 2011;4(3):164-6.

Elevated serum level of bilirubin is a common manifestation which is occurred in several diseases. Hyperbilirubinemia can manifest either conjugated or unconjugated. Conjugated or direct hyperbilirubinemia usually are caused by hepatocellular diseases or cholestatic liver diseases. Merely conjugated hyperbilirubinemia...

Cite
Lahmi F, Roshani M, Khosravi K, et al. Dubin-Johnson syndrome presenting after acute viral hepatitis. Gastroenterol Hepatol Bed Bench. 2011;4(3):164-6
Lahmi, F., Roshani, M., Khosravi, K., Azizi, M., Mohebbi, S. R., & Zali, M. R. (2011). Dubin-Johnson syndrome presenting after acute viral hepatitis. Gastroenterology and hepatology from bed to bench, 4(3), 164-6.
Lahmi, Farhad, et al. "Dubin-Johnson syndrome presenting after acute viral hepatitis." Gastroenterology and hepatology from bed to bench vol. 4,3 (2011): 164-6.
Lahmi F, Roshani M, Khosravi K, Azizi M, Mohebbi SR, Zali MR. Dubin-Johnson syndrome presenting after acute viral hepatitis. Gastroenterol Hepatol Bed Bench. 2011;4(3):164-6. PMID: 24834177; PMCID: PMC4017419.
Copy Download .nbib Format: NLM
Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.

World journal of hepatology

Puchakayala BK, Verma S, Kanwar P, Hart J, Sanivarapu RR, Mohanty SR.
PMID: 26557954
World J Hepatol. 2015 Nov 08;7(25):2610-8. doi: 10.4254/wjh.v7.i25.2610.

AIM: To study clinical and histopathological features of nonalcoholic fatty liver disease (NAFLD) in patients with and without type 2 diabetes mellitus (T2DM) using updated nonalcoholic steatohepatitis clinical research network (NASH-CRN) grading system.METHODS: We retrospectively analyzed data of 235...

Cite
Puchakayala BK, Verma S, Kanwar P, et al. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol. 2015;7(25):2610-8doi: 10.4254/wjh.v7.i25.2610.
Puchakayala, B. K., Verma, S., Kanwar, P., Hart, J., Sanivarapu, R. R., & Mohanty, S. R. (2015). Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World journal of hepatology, 7(25), 2610-8. https://doi.org/10.4254/wjh.v7.i25.2610
Puchakayala, Bharat K, et al. "Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease." World journal of hepatology vol. 7,25 (2015): 2610-8. doi: https://doi.org/10.4254/wjh.v7.i25.2610
Puchakayala BK, Verma S, Kanwar P, Hart J, Sanivarapu RR, Mohanty SR. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol. 2015 Nov 08;7(25):2610-8. doi: 10.4254/wjh.v7.i25.2610. PMID: 26557954; PMCID: PMC4635147.
Copy Download .nbib Format: NLM
Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?.

BMJ open gastroenterology

Kaspar MB, Sterling RK.
PMID: 26966552
BMJ Open Gastroenterol. 2016 Mar 02;3(1):e000072. doi: 10.1136/bmjgast-2015-000072. eCollection 2016.

OBJECTIVE: Hyperbilirubinaemia (HB) is common in HIV and hepatitis C virus (HIV-HCV) co-infected patients and poses a unique challenge in management as it may be due to medications such as the protease inhibitors (PIs) or to hepatic dysfunction. There...

Cite
Kaspar MB, Sterling RK. Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ Open Gastroenterol. 2016;3(1):e000072doi: 10.1136/bmjgast-2015-000072.
Kaspar, M. B., & Sterling, R. K. (2016). Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ open gastroenterology, 3(1), e000072. https://doi.org/10.1136/bmjgast-2015-000072
Kaspar, Matthew B, and Sterling, Richard K. "Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?." BMJ open gastroenterology vol. 3,1 (2016): e000072. doi: https://doi.org/10.1136/bmjgast-2015-000072
Kaspar MB, Sterling RK. Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ Open Gastroenterol. 2016 Mar 02;3(1):e000072. doi: 10.1136/bmjgast-2015-000072. eCollection 2016. PMID: 26966552; PMCID: PMC4780040.
Copy Download .nbib Format: NLM
Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia.

Oncotarget

Schaefer B, Behrends S.
PMID: 28978042
Oncotarget. 2017 Jun 27;8(40):67406-67421. doi: 10.18632/oncotarget.18684. eCollection 2017 Sep 15.

Heme oxygenase-1 (HO-1) degrades heme to bilirubin. In addition, it is upregulated in malignant disease and has been described as an important factor for cancer prognosis and therapy. Under physiological conditions HO-1 is anchored to the endoplasmic reticulum (ER)....

Cite
Schaefer B, Behrends S. Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia. Oncotarget. 2017;8(40):67406-67421doi: 10.18632/oncotarget.18684.
Schaefer, B., & Behrends, S. (2017). Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia. Oncotarget, 8(40), 67406-67421. https://doi.org/10.18632/oncotarget.18684
Schaefer, Bianca, and Behrends, Soenke. "Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia." Oncotarget vol. 8,40 (2017): 67406-67421. doi: https://doi.org/10.18632/oncotarget.18684
Schaefer B, Behrends S. Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia. Oncotarget. 2017 Jun 27;8(40):67406-67421. doi: 10.18632/oncotarget.18684. eCollection 2017 Sep 15. PMID: 28978042; PMCID: PMC5620182.
Copy Download .nbib Format: NLM
Therapeutic efficacy of ethanolic extract of Aerva javanica aerial parts in the amelioration of CCl4-induced hepatotoxicity and oxidative damage in rats.

Food & nutrition research

Arbab AH, Parvez MK, Al-Dosari MS, Al-Rehaily AJ, Ibrahim KE, Alam P, Alsaid MS, Rafatullah S.
PMID: 27059702
Food Nutr Res. 2016 Apr 07;60:30864. doi: 10.3402/fnr.v60.30864. eCollection 2016.

BACKGROUND: Liver diseases, the fifth most common cause of global death, can be metabolic, toxin-induced, or infective. Though approximately 35 Saudi medicinal plants are traditionally used to treat liver disorders, the hepatoprotective potential of Aerva javanica has not been...

Cite
Arbab AH, Parvez MK, Al-Dosari MS, et al. Therapeutic efficacy of ethanolic extract of Aerva javanica aerial parts in the amelioration of CCl4-induced hepatotoxicity and oxidative damage in rats. Food Nutr Res. 2016;60:30864doi: 10.3402/fnr.v60.30864.
Arbab, A. H., Parvez, M. K., Al-Dosari, M. S., Al-Rehaily, A. J., Ibrahim, K. E., Alam, P., Alsaid, M. S., & Rafatullah, S. (2016). Therapeutic efficacy of ethanolic extract of Aerva javanica aerial parts in the amelioration of CCl4-induced hepatotoxicity and oxidative damage in rats. Food & nutrition research, 6030864. https://doi.org/10.3402/fnr.v60.30864
Arbab, Ahmed H, et al. "Therapeutic efficacy of ethanolic extract of Aerva javanica aerial parts in the amelioration of CCl4-induced hepatotoxicity and oxidative damage in rats." Food & nutrition research vol. 60 (2016): 30864. doi: https://doi.org/10.3402/fnr.v60.30864
Arbab AH, Parvez MK, Al-Dosari MS, Al-Rehaily AJ, Ibrahim KE, Alam P, Alsaid MS, Rafatullah S. Therapeutic efficacy of ethanolic extract of Aerva javanica aerial parts in the amelioration of CCl4-induced hepatotoxicity and oxidative damage in rats. Food Nutr Res. 2016 Apr 07;60:30864. doi: 10.3402/fnr.v60.30864. eCollection 2016. PMID: 27059702; PMCID: PMC4826463.
Copy Download .nbib Format: NLM
Biochemical Markers of Bone Turnover in Patients with β-Thalassemia Major: A Single Center Study from Southern Pakistan.

Advances in hematology

Sultan S, Irfan SM, Ahmed SI.
PMID: 27006658
Adv Hematol. 2016;2016:5437609. doi: 10.1155/2016/5437609. Epub 2016 Feb 23.

Objectives. Skeletal complications in β-homozygous thalassemic patients are uncommon but often debilitating, even amongst children and adolescent patients with well maintained transfusion and chelation therapy. The aim is to evaluate the biochemical markers of bone turnover in regularly transfused...

Cite
Sultan S, Irfan SM, Ahmed SI. Biochemical Markers of Bone Turnover in Patients with β-Thalassemia Major: A Single Center Study from Southern Pakistan. Adv Hematol. 2016;2016:5437609doi: 10.1155/2016/5437609.
Sultan, S., Irfan, S. M., & Ahmed, S. I. (2016). Biochemical Markers of Bone Turnover in Patients with β-Thalassemia Major: A Single Center Study from Southern Pakistan. Advances in hematology, 20165437609. https://doi.org/10.1155/2016/5437609
Sultan, Sadia, et al. "Biochemical Markers of Bone Turnover in Patients with β-Thalassemia Major: A Single Center Study from Southern Pakistan." Advances in hematology vol. 2016 (2016): 5437609. doi: https://doi.org/10.1155/2016/5437609
Sultan S, Irfan SM, Ahmed SI. Biochemical Markers of Bone Turnover in Patients with β-Thalassemia Major: A Single Center Study from Southern Pakistan. Adv Hematol. 2016;2016:5437609. doi: 10.1155/2016/5437609. Epub 2016 Feb 23. PMID: 27006658; PMCID: PMC4783526.
Copy Download .nbib Format: NLM
Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.

Clinical and translational gastroenterology

Sclair SN, Little E, Levy C.
PMID: 26312413
Clin Transl Gastroenterol. 2015 Aug 27;6:e109. doi: 10.1038/ctg.2015.33.

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic, cholestatic diseases of the liver with common clinical manifestations. Early diagnosis and treatment of PBC slows progression and decreases the need for transplant. However, one-third of patients will...

Cite
Sclair SN, Little E, Levy C. Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin Transl Gastroenterol. 2015;6:e109doi: 10.1038/ctg.2015.33.
Sclair, S. N., Little, E., & Levy, C. (2015). Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinical and translational gastroenterology, 6e109. https://doi.org/10.1038/ctg.2015.33
Sclair, Seth N, et al. "Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis." Clinical and translational gastroenterology vol. 6 (2015): e109. doi: https://doi.org/10.1038/ctg.2015.33
Sclair SN, Little E, Levy C. Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin Transl Gastroenterol. 2015 Aug 27;6:e109. doi: 10.1038/ctg.2015.33. PMID: 26312413; PMCID: PMC4816277.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 4486 entries